Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
The most eye-catching filings in the latest ORTEX insider dataset come from two very different companies. Both saw management buying shares in the open market, the kind of discretionary move that carries more weight than a routine stock award.
UBER President and COO Andrew Gordon MacDonald filed purchases totalling roughly $5.3M across two transactions on 4 September, picking up around 70,000 shares at prices near $75. That is a direct bet with personal money at a $146B market-cap company. Short interest stands at just 2.4% of free float, so this is not a squeeze play. It reads as a straightforward expression of confidence.
At smaller-cap biotech HELP, two directors each bought 100,000 shares on 3 to 4 September, spending roughly $1.2M apiece. Helus Pharma carries a market cap of $862M and a short interest of 6.3% of free float. Cluster buying by multiple board members in a brief window is often the clearest insider signal available.
On the sell side, JPMorgan Chase trimmed its 5% positions in several Hong Kong-listed names, including Kingdee International and Sunny Optical Technology, shedding $85M and $71M respectively. These are institutional portfolio moves rather than insider conviction signals.
Netmarble, the main shareholder in South Korean appliance company COWAY, filed four separate buy transactions during the week of 3 to 8 September, each around $1.8M to $2M. Persistent buying at regular intervals can indicate a shareholder building toward a threshold.
The Uber COO trade stands out as the strongest signal. Open-market purchases by a sitting C-level officer at a mega-cap company are rare enough to be worth tracking.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
